ReP USP - Resultado da busca

Artigo de periodico
Optimizing therapeutic drug monitoring in pregnant women: a critical literature review (2023)
Moreira, Fernanda de Lima ; Benzi, Jhohann Richard de Lima ; Pinto, Leonardo; Thomaz, Matheus de Lucca; Duarte, Geraldo ; Lanchote, Vera Lucia
Source: Therapeutic Drug Monitoring. Unidades: FMRP, FCFRP
Subjects: ANTIMALÁRICOS, GRAVIDEZ, MEDICAMENTO
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
MOREIRA, Fernanda de Lima et al. Optimizing therapeutic drug monitoring in pregnant women: a critical literature review. Therapeutic Drug Monitoring, v. 45, n. 2, p. 159-172, 2023Tradução . . Disponível em: https://doi.org/10.1097/FTD.0000000000001039. Acesso em: 16 nov. 2024.
APA
Moreira, F. de L., Benzi, J. R. de L., Pinto, L., Thomaz, M. de L., Duarte, G., & Lanchote, V. L. (2023). Optimizing therapeutic drug monitoring in pregnant women: a critical literature review. Therapeutic Drug Monitoring, 45( 2), 159-172. doi:10.1097/FTD.0000000000001039
NLM
Moreira F de L, Benzi JR de L, Pinto L, Thomaz M de L, Duarte G, Lanchote VL. Optimizing therapeutic drug monitoring in pregnant women: a critical literature review [Internet]. Therapeutic Drug Monitoring. 2023 ; 45( 2): 159-172.[citado 2024 nov. 16 ] Available from: https://doi.org/10.1097/FTD.0000000000001039
Vancouver
Moreira F de L, Benzi JR de L, Pinto L, Thomaz M de L, Duarte G, Lanchote VL. Optimizing therapeutic drug monitoring in pregnant women: a critical literature review [Internet]. Therapeutic Drug Monitoring. 2023 ; 45( 2): 159-172.[citado 2024 nov. 16 ] Available from: https://doi.org/10.1097/FTD.0000000000001039
Artigo de periodico
P-Glycoprotein and organic anion transporter polypeptide 1B/breast cancer resistance protein drug transporter activity in pregnant women living with HIV (2023)
Moreira, Fernanda de Lima; Melli, Patrícia Pereira dos Santos; Marques, Maria Paula ; Rocha, Adriana; Nardotto, Glauco Henrique Balthazar ; Duarte, Geraldo; Lanchote, Vera Lucia
Source: The Journal of Clinical Pharmacology. Unidades: FCFRP, FMRP
Subjects: NEOPLASIAS MAMÁRIAS, INFECÇÕES POR HIV, INTERAÇÃO DE MEDICAMENTOS, GRAVIDEZ, FARMACOTERAPIA
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
MOREIRA, Fernanda de Lima et al. P-Glycoprotein and organic anion transporter polypeptide 1B/breast cancer resistance protein drug transporter activity in pregnant women living with HIV. The Journal of Clinical Pharmacology, v. 63, n. 2, p. 219-227, 2023Tradução . . Disponível em: https://doi.org/10.1002/jcph.2152. Acesso em: 16 nov. 2024.
APA
Moreira, F. de L., Melli, P. P. dos S., Marques, M. P., Rocha, A., Nardotto, G. H. B., Duarte, G., & Lanchote, V. L. (2023). P-Glycoprotein and organic anion transporter polypeptide 1B/breast cancer resistance protein drug transporter activity in pregnant women living with HIV. The Journal of Clinical Pharmacology, 63( 2), 219-227. doi:10.1002/jcph.2152
NLM
Moreira F de L, Melli PP dos S, Marques MP, Rocha A, Nardotto GHB, Duarte G, Lanchote VL. P-Glycoprotein and organic anion transporter polypeptide 1B/breast cancer resistance protein drug transporter activity in pregnant women living with HIV [Internet]. The Journal of Clinical Pharmacology. 2023 ; 63( 2): 219-227.[citado 2024 nov. 16 ] Available from: https://doi.org/10.1002/jcph.2152
Vancouver
Moreira F de L, Melli PP dos S, Marques MP, Rocha A, Nardotto GHB, Duarte G, Lanchote VL. P-Glycoprotein and organic anion transporter polypeptide 1B/breast cancer resistance protein drug transporter activity in pregnant women living with HIV [Internet]. The Journal of Clinical Pharmacology. 2023 ; 63( 2): 219-227.[citado 2024 nov. 16 ] Available from: https://doi.org/10.1002/jcph.2152
Artigo de periodico
Enhanced elimination of betamethasone in dichorionic twin pregnancies (2022)
Rodrigues, Grazielle de Fátima Pinto ; Benzi, Jhohann Richard de Lima ; Matos, Luísa Helena de Castro; Freitas, Stella Felippe de; Marques, Maria Paula ; Cavalli, Ricardo de Carvalho; Moisés, Elaine Christine Dantas ; Duarte, Geraldo; Lanchote, Vera Lucia ; Marcolin, Alessandra Cristina
Source: British Journal of Clinical Pharmacology. Unidades: FMRP, FCFRP
Subjects: GRAVIDEZ, FARMACOCINÉTICA, PLACENTA
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
RODRIGUES, Grazielle de Fátima Pinto et al. Enhanced elimination of betamethasone in dichorionic twin pregnancies. British Journal of Clinical Pharmacology, v. 88, n. 4, p. 1897-1903, 2022Tradução . . Disponível em: https://doi.org/10.1111/bcp.15111. Acesso em: 16 nov. 2024.
APA
Rodrigues, G. de F. P., Benzi, J. R. de L., Matos, L. H. de C., Freitas, S. F. de, Marques, M. P., Cavalli, R. de C., et al. (2022). Enhanced elimination of betamethasone in dichorionic twin pregnancies. British Journal of Clinical Pharmacology, 88( 4), 1897-1903. doi:10.1111/bcp.15111
NLM
Rodrigues G de FP, Benzi JR de L, Matos LH de C, Freitas SF de, Marques MP, Cavalli R de C, Moisés ECD, Duarte G, Lanchote VL, Marcolin AC. Enhanced elimination of betamethasone in dichorionic twin pregnancies [Internet]. British Journal of Clinical Pharmacology. 2022 ; 88( 4): 1897-1903.[citado 2024 nov. 16 ] Available from: https://doi.org/10.1111/bcp.15111
Vancouver
Rodrigues G de FP, Benzi JR de L, Matos LH de C, Freitas SF de, Marques MP, Cavalli R de C, Moisés ECD, Duarte G, Lanchote VL, Marcolin AC. Enhanced elimination of betamethasone in dichorionic twin pregnancies [Internet]. British Journal of Clinical Pharmacology. 2022 ; 88( 4): 1897-1903.[citado 2024 nov. 16 ] Available from: https://doi.org/10.1111/bcp.15111
Artigo de periodico
Pharmacogenetic predictors of variability in efavirenz pharmacokinetics in an admixed Brazilian HIV cohort (2022)
Ximenez, João Paulo Bianchi; Elias, Anna Beatriz Ribeiro; Nardotto, Glauco Henrique Balthazar ; Barroso, Paulo Feijó; Bollela, Valdes Roberto; Lanchote, Vera Lucia ; Suarez-Kurtz, Guilherme
Source: British Journal of Clinical Pharmacology. Unidades: FMRP, FCFRP
Subjects: FARMACOCINÉTICA, HIV, CITOCROMO P-450, GENÓTIPOS, INFECÇÕES POR HIV, FARMACOGENÉTICA, POLIMORFISMO
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
XIMENEZ, João Paulo Bianchi et al. Pharmacogenetic predictors of variability in efavirenz pharmacokinetics in an admixed Brazilian HIV cohort. British Journal of Clinical Pharmacology, v. 88, n. 10, p. 4585-4594, 2022Tradução . . Disponível em: https://doi.org/10.1111/bcp.15387. Acesso em: 16 nov. 2024.
APA
Ximenez, J. P. B., Elias, A. B. R., Nardotto, G. H. B., Barroso, P. F., Bollela, V. R., Lanchote, V. L., & Suarez-Kurtz, G. (2022). Pharmacogenetic predictors of variability in efavirenz pharmacokinetics in an admixed Brazilian HIV cohort. British Journal of Clinical Pharmacology, 88( 10), 4585-4594. doi:10.1111/bcp.15387
NLM
Ximenez JPB, Elias ABR, Nardotto GHB, Barroso PF, Bollela VR, Lanchote VL, Suarez-Kurtz G. Pharmacogenetic predictors of variability in efavirenz pharmacokinetics in an admixed Brazilian HIV cohort [Internet]. British Journal of Clinical Pharmacology. 2022 ; 88( 10): 4585-4594.[citado 2024 nov. 16 ] Available from: https://doi.org/10.1111/bcp.15387
Vancouver
Ximenez JPB, Elias ABR, Nardotto GHB, Barroso PF, Bollela VR, Lanchote VL, Suarez-Kurtz G. Pharmacogenetic predictors of variability in efavirenz pharmacokinetics in an admixed Brazilian HIV cohort [Internet]. British Journal of Clinical Pharmacology. 2022 ; 88( 10): 4585-4594.[citado 2024 nov. 16 ] Available from: https://doi.org/10.1111/bcp.15387
Artigo de periodico
No implication of HIV coinfection on the plasma exposure to rifampicin, pyrazinamide, and ethambutol in tuberculosis patients (2022)
Nardotto, Glauco Henrique Balthazar ; Bollela, Valdes Roberto; Rocha, Adriana; Della Pasqua, Oscar; Lanchote, Vera Lucia
Source: Clinical and Translational Science. Unidades: FMRP, FCFRP
Subjects: HIV, FARMACOCINÉTICA, TUBERCULOSE, ESTUDOS PROSPECTIVOS
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
NARDOTTO, Glauco Henrique Balthazar et al. No implication of HIV coinfection on the plasma exposure to rifampicin, pyrazinamide, and ethambutol in tuberculosis patients. Clinical and Translational Science, v. 15, p. 514-523, 2022Tradução . . Disponível em: https://doi.org/10.1111/cts.13169. Acesso em: 16 nov. 2024.
APA
Nardotto, G. H. B., Bollela, V. R., Rocha, A., Della Pasqua, O., & Lanchote, V. L. (2022). No implication of HIV coinfection on the plasma exposure to rifampicin, pyrazinamide, and ethambutol in tuberculosis patients. Clinical and Translational Science, 15, 514-523. doi:10.1111/cts.13169
NLM
Nardotto GHB, Bollela VR, Rocha A, Della Pasqua O, Lanchote VL. No implication of HIV coinfection on the plasma exposure to rifampicin, pyrazinamide, and ethambutol in tuberculosis patients [Internet]. Clinical and Translational Science. 2022 ; 15 514-523.[citado 2024 nov. 16 ] Available from: https://doi.org/10.1111/cts.13169
Vancouver
Nardotto GHB, Bollela VR, Rocha A, Della Pasqua O, Lanchote VL. No implication of HIV coinfection on the plasma exposure to rifampicin, pyrazinamide, and ethambutol in tuberculosis patients [Internet]. Clinical and Translational Science. 2022 ; 15 514-523.[citado 2024 nov. 16 ] Available from: https://doi.org/10.1111/cts.13169
Artigo de periodico
Potential cannabidiol (CBD) repurposing as antibacterial and promising therapy of CBD plus polymyxin B (PB) against PB-resistant gram-negative bacilli (2022)
Abichabki, Nathália de Lima Martins ; Zacharias, Luísa Vieira; Moreira, Natália Columbaro; Bellíssimo-Rodrigues, Fernando; Moreira, Fernanda L.; Benzi, Jhohann Richard de Lima ; Ogasawara, Tânia Mara Casare; Ferreira, Joseane Cristina; Ribeiro, Camila M.; Pavan, Fernando R.; Pereira, Leonardo Régis Leira; Brancini, Guilherme Thomaz Pereira; Braga, Gilberto Ubida Leite; Zuardi, Antonio Waldo; Hallak, Jaime Eduardo Cecilio ; Crippa, José Alexandre de Souza ; Lanchote, Vera Lucia ; Cantón, Rafael; Darini, Ana Lúcia da Costa ; Andrade, Leonardo Neves de
Source: Scientific Reports. Unidades: FMRP, FCFRP
Subjects: CANABINOIDES, REPOSICIONAMENTO DE FÁRMACOS, RESISTÊNCIA MICROBIANA ÀS DROGAS, SINERGISMO DE DROGAS, TESTES DE SENSIBILIDADE MICROBIANA, BACTÉRIAS GRAM-NEGATIVAS
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
ABICHABKI, Nathália de Lima Martins et al. Potential cannabidiol (CBD) repurposing as antibacterial and promising therapy of CBD plus polymyxin B (PB) against PB-resistant gram-negative bacilli. Scientific Reports, v. 12, p. 1-15, 2022Tradução . . Disponível em: https://doi.org/10.1038/s41598-022-10393-8. Acesso em: 16 nov. 2024.
APA
Abichabki, N. de L. M., Zacharias, L. V., Moreira, N. C., Bellíssimo-Rodrigues, F., Moreira, F. L., Benzi, J. R. de L., et al. (2022). Potential cannabidiol (CBD) repurposing as antibacterial and promising therapy of CBD plus polymyxin B (PB) against PB-resistant gram-negative bacilli. Scientific Reports, 12, 1-15. doi:10.1038/s41598-022-10393-8
NLM
Abichabki N de LM, Zacharias LV, Moreira NC, Bellíssimo-Rodrigues F, Moreira FL, Benzi JR de L, Ogasawara TMC, Ferreira JC, Ribeiro CM, Pavan FR, Pereira LRL, Brancini GTP, Braga GUL, Zuardi AW, Hallak JEC, Crippa JA de S, Lanchote VL, Cantón R, Darini AL da C, Andrade LN de. Potential cannabidiol (CBD) repurposing as antibacterial and promising therapy of CBD plus polymyxin B (PB) against PB-resistant gram-negative bacilli [Internet]. Scientific Reports. 2022 ; 12 1-15.[citado 2024 nov. 16 ] Available from: https://doi.org/10.1038/s41598-022-10393-8
Vancouver
Abichabki N de LM, Zacharias LV, Moreira NC, Bellíssimo-Rodrigues F, Moreira FL, Benzi JR de L, Ogasawara TMC, Ferreira JC, Ribeiro CM, Pavan FR, Pereira LRL, Brancini GTP, Braga GUL, Zuardi AW, Hallak JEC, Crippa JA de S, Lanchote VL, Cantón R, Darini AL da C, Andrade LN de. Potential cannabidiol (CBD) repurposing as antibacterial and promising therapy of CBD plus polymyxin B (PB) against PB-resistant gram-negative bacilli [Internet]. Scientific Reports. 2022 ; 12 1-15.[citado 2024 nov. 16 ] Available from: https://doi.org/10.1038/s41598-022-10393-8
Artigo de periodico
Translation, cross-cultural adaptation, and validation of the portuguese version of the Rotterdam Elderly Pain Observation Scale (2021)
Seixas-Moizes, Julieta; Boerlage, Anneke; Lia, Érica Negrini; Santos, Lucas Emmanuel Lopes e; Zucoloto, Miriane Lucindo; Dach, Fabíola; Papassidero, Priscila Colavite; Wichert-Ana, Laís Almeida Leal; Della Pasqua, Oscar; Wiesebron, Marianne Louise; Icuma, Tatiana Reis; Lanchote, Vera Lucia; Coelho, Eduardo Barbosa; Tibboel, Dick; Wichert-Ana, Lauro
Source: Dementia and Geriatric Cognitive Disorders Extra. Unidades: FMRP, FCFRP
Subjects: DOR, IDOSOS, ESTUDOS DE VALIDAÇÃO, DEMÊNCIA, ESTUDOS MULTICÊNTRICOS
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
SEIXAS-MOIZES, Julieta et al. Translation, cross-cultural adaptation, and validation of the portuguese version of the Rotterdam Elderly Pain Observation Scale. Dementia and Geriatric Cognitive Disorders Extra, v. 11, n. 3, p. 314-323, 2021Tradução . . Disponível em: https://doi.org/10.1159/000520455. Acesso em: 16 nov. 2024.
APA
Seixas-Moizes, J., Boerlage, A., Lia, É. N., Santos, L. E. L. e, Zucoloto, M. L., Dach, F., et al. (2021). Translation, cross-cultural adaptation, and validation of the portuguese version of the Rotterdam Elderly Pain Observation Scale. Dementia and Geriatric Cognitive Disorders Extra, 11( 3), 314-323. doi:10.1159/000520455
NLM
Seixas-Moizes J, Boerlage A, Lia ÉN, Santos LEL e, Zucoloto ML, Dach F, Papassidero PC, Wichert-Ana LAL, Della Pasqua O, Wiesebron ML, Icuma TR, Lanchote VL, Coelho EB, Tibboel D, Wichert-Ana L. Translation, cross-cultural adaptation, and validation of the portuguese version of the Rotterdam Elderly Pain Observation Scale [Internet]. Dementia and Geriatric Cognitive Disorders Extra. 2021 ; 11( 3): 314-323.[citado 2024 nov. 16 ] Available from: https://doi.org/10.1159/000520455
Vancouver
Seixas-Moizes J, Boerlage A, Lia ÉN, Santos LEL e, Zucoloto ML, Dach F, Papassidero PC, Wichert-Ana LAL, Della Pasqua O, Wiesebron ML, Icuma TR, Lanchote VL, Coelho EB, Tibboel D, Wichert-Ana L. Translation, cross-cultural adaptation, and validation of the portuguese version of the Rotterdam Elderly Pain Observation Scale [Internet]. Dementia and Geriatric Cognitive Disorders Extra. 2021 ; 11( 3): 314-323.[citado 2024 nov. 16 ] Available from: https://doi.org/10.1159/000520455
Artigo de periodico
Determination of misoprostol acid in plasma samples by UPLC–MS/MS with application in a maternal-fetal pharmacokinetic study following a low misoprostol dose vaginally to induce labor (2021)
Filgueira, Gabriela Campos de Oliveira; Rodrigues, Grazielle de Fátima Pinto; Benzi, Jhohann Richard de Lima ; Nardotto, Glauco Henrique Balthazar ; Marques, Maria Paula ; Lanchote, Vera Lucia ; Cavalli, Ricardo de Carvalho
Source: Journal of Pharmaceutical and Biomedical Analysis. Unidades: FCFRP, FMRP
Subjects: TRABALHO DE PARTO INDUZIDO, PROSTAGLANDINAS SINTÉTICAS, CROMATOGRAFIA LÍQUIDA DE ALTA PRESSÃO, GRAVIDEZ, HEMORRAGIA, PLACENTA
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
FILGUEIRA, Gabriela Campos de Oliveira et al. Determination of misoprostol acid in plasma samples by UPLC–MS/MS with application in a maternal-fetal pharmacokinetic study following a low misoprostol dose vaginally to induce labor. Journal of Pharmaceutical and Biomedical Analysis, v. 202, p. 1-7, 2021Tradução . . Disponível em: https://doi.org/10.1016/j.jpba.2021.114138. Acesso em: 16 nov. 2024.
APA
Filgueira, G. C. de O., Rodrigues, G. de F. P., Benzi, J. R. de L., Nardotto, G. H. B., Marques, M. P., Lanchote, V. L., & Cavalli, R. de C. (2021). Determination of misoprostol acid in plasma samples by UPLC–MS/MS with application in a maternal-fetal pharmacokinetic study following a low misoprostol dose vaginally to induce labor. Journal of Pharmaceutical and Biomedical Analysis, 202, 1-7. doi:10.1016/j.jpba.2021.114138
NLM
Filgueira GC de O, Rodrigues G de FP, Benzi JR de L, Nardotto GHB, Marques MP, Lanchote VL, Cavalli R de C. Determination of misoprostol acid in plasma samples by UPLC–MS/MS with application in a maternal-fetal pharmacokinetic study following a low misoprostol dose vaginally to induce labor [Internet]. Journal of Pharmaceutical and Biomedical Analysis. 2021 ; 202 1-7.[citado 2024 nov. 16 ] Available from: https://doi.org/10.1016/j.jpba.2021.114138
Vancouver
Filgueira GC de O, Rodrigues G de FP, Benzi JR de L, Nardotto GHB, Marques MP, Lanchote VL, Cavalli R de C. Determination of misoprostol acid in plasma samples by UPLC–MS/MS with application in a maternal-fetal pharmacokinetic study following a low misoprostol dose vaginally to induce labor [Internet]. Journal of Pharmaceutical and Biomedical Analysis. 2021 ; 202 1-7.[citado 2024 nov. 16 ] Available from: https://doi.org/10.1016/j.jpba.2021.114138
Artigo de periodico
Chiral transplacental pharmacokinetics of fexofenadine: impact of P-Glycoprotein inhibitor fluoxetine using the human placental perfusion model (2021)
Pinto, Leonardo Santos Ribeiro; Bapat, Priya; Moreira, Fernanda de Lima; Lubetsky, Angelika; Cavalli, Ricardo de Carvalho; Berger, Howard; Lanchote, Vera Lucia ; Koren, Gideon
Source: Pharmaceutical Research. Unidades: FCFRP, FMRP
Subjects: ANTAGONISTAS, FARMACOTERAPIA, ANTIDEPRESSIVOS, PLACENTA, COMPLICAÇÕES NA GRAVIDEZ, ANTI-HISTAMÍNICOS, FARMACOCINÉTICA
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
PINTO, Leonardo Santos Ribeiro et al. Chiral transplacental pharmacokinetics of fexofenadine: impact of P-Glycoprotein inhibitor fluoxetine using the human placental perfusion model. Pharmaceutical Research, v. 38, n. 4, p. 647-655, 2021Tradução . . Disponível em: https://doi.org/10.1007/s11095-021-03035-7. Acesso em: 16 nov. 2024.
APA
Pinto, L. S. R., Bapat, P., Moreira, F. de L., Lubetsky, A., Cavalli, R. de C., Berger, H., et al. (2021). Chiral transplacental pharmacokinetics of fexofenadine: impact of P-Glycoprotein inhibitor fluoxetine using the human placental perfusion model. Pharmaceutical Research, 38( 4), 647-655. doi:10.1007/s11095-021-03035-7
NLM
Pinto LSR, Bapat P, Moreira F de L, Lubetsky A, Cavalli R de C, Berger H, Lanchote VL, Koren G. Chiral transplacental pharmacokinetics of fexofenadine: impact of P-Glycoprotein inhibitor fluoxetine using the human placental perfusion model [Internet]. Pharmaceutical Research. 2021 ; 38( 4): 647-655.[citado 2024 nov. 16 ] Available from: https://doi.org/10.1007/s11095-021-03035-7
Vancouver
Pinto LSR, Bapat P, Moreira F de L, Lubetsky A, Cavalli R de C, Berger H, Lanchote VL, Koren G. Chiral transplacental pharmacokinetics of fexofenadine: impact of P-Glycoprotein inhibitor fluoxetine using the human placental perfusion model [Internet]. Pharmaceutical Research. 2021 ; 38( 4): 647-655.[citado 2024 nov. 16 ] Available from: https://doi.org/10.1007/s11095-021-03035-7
Artigo de periodico
Sensitive LC-MS/MS methods for amphotericin B analysis in cerebrospinal fluid, plasma, plasma ultrafiltrate, and urine: application to clinical pharmacokinetics (2021)
Pippa, Leandro Francisco ; Pereira, Maria Paula Marques ; Silva, Anna Christina Tojal da; Vilar, Fernando Crivelenti; Haes, Tissiana Marques de; Fonseca, Benedito Antonio Lopes da; Martinez, Roberto ; Coelho, Eduardo Barbosa ; Wichert-Ana, Lauro; Lanchote, Vera Lucia
Source: Frontiers in Chemistry. Unidades: FCFRP, FMRP, EERP
Subjects: ANTIFÚNGICOS, LÍQUIDO CEFALORRAQUIDIANO, FARMACOCINÉTICA, PLASMA
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
PIPPA, Leandro Francisco et al. Sensitive LC-MS/MS methods for amphotericin B analysis in cerebrospinal fluid, plasma, plasma ultrafiltrate, and urine: application to clinical pharmacokinetics. Frontiers in Chemistry, v. 9, p. 1-14, 2021Tradução . . Disponível em: https://doi.org/10.3389/fchem.2021.782131. Acesso em: 16 nov. 2024.
APA
Pippa, L. F., Pereira, M. P. M., Silva, A. C. T. da, Vilar, F. C., Haes, T. M. de, Fonseca, B. A. L. da, et al. (2021). Sensitive LC-MS/MS methods for amphotericin B analysis in cerebrospinal fluid, plasma, plasma ultrafiltrate, and urine: application to clinical pharmacokinetics. Frontiers in Chemistry, 9, 1-14. doi:10.3389/fchem.2021.782131
NLM
Pippa LF, Pereira MPM, Silva ACT da, Vilar FC, Haes TM de, Fonseca BAL da, Martinez R, Coelho EB, Wichert-Ana L, Lanchote VL. Sensitive LC-MS/MS methods for amphotericin B analysis in cerebrospinal fluid, plasma, plasma ultrafiltrate, and urine: application to clinical pharmacokinetics [Internet]. Frontiers in Chemistry. 2021 ; 9 1-14.[citado 2024 nov. 16 ] Available from: https://doi.org/10.3389/fchem.2021.782131
Vancouver
Pippa LF, Pereira MPM, Silva ACT da, Vilar FC, Haes TM de, Fonseca BAL da, Martinez R, Coelho EB, Wichert-Ana L, Lanchote VL. Sensitive LC-MS/MS methods for amphotericin B analysis in cerebrospinal fluid, plasma, plasma ultrafiltrate, and urine: application to clinical pharmacokinetics [Internet]. Frontiers in Chemistry. 2021 ; 9 1-14.[citado 2024 nov. 16 ] Available from: https://doi.org/10.3389/fchem.2021.782131
Artigo de periodico
Nifedipine does not alter the pharmacokinetics of venlafaxine enantiomers in healthy subjects phenotyped for CYP2D6, CYP2C19, and CYP3A (2021)
Tozatto, Eduardo; Benzi, Jhohann Richard de Lima ; Rocha, Adriana; Coelho, Eduardo Barbosa ; Lanchote, Vera Lucia
Source: The Journal of Clinical Pharmacology. Unidades: FCFRP, FMRP
Subjects: FÁRMACOS, HIPERTENSÃO, FARMACOCINÉTICA, ANTIDEPRESSIVOS
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
TOZATTO, Eduardo et al. Nifedipine does not alter the pharmacokinetics of venlafaxine enantiomers in healthy subjects phenotyped for CYP2D6, CYP2C19, and CYP3A. The Journal of Clinical Pharmacology, v. 61, n. 3, p. 319-327, 2021Tradução . . Disponível em: https://doi.org/10.1002/jcph.1745. Acesso em: 16 nov. 2024.
APA
Tozatto, E., Benzi, J. R. de L., Rocha, A., Coelho, E. B., & Lanchote, V. L. (2021). Nifedipine does not alter the pharmacokinetics of venlafaxine enantiomers in healthy subjects phenotyped for CYP2D6, CYP2C19, and CYP3A. The Journal of Clinical Pharmacology, 61( 3), 319-327. doi:10.1002/jcph.1745
NLM
Tozatto E, Benzi JR de L, Rocha A, Coelho EB, Lanchote VL. Nifedipine does not alter the pharmacokinetics of venlafaxine enantiomers in healthy subjects phenotyped for CYP2D6, CYP2C19, and CYP3A [Internet]. The Journal of Clinical Pharmacology. 2021 ; 61( 3): 319-327.[citado 2024 nov. 16 ] Available from: https://doi.org/10.1002/jcph.1745
Vancouver
Tozatto E, Benzi JR de L, Rocha A, Coelho EB, Lanchote VL. Nifedipine does not alter the pharmacokinetics of venlafaxine enantiomers in healthy subjects phenotyped for CYP2D6, CYP2C19, and CYP3A [Internet]. The Journal of Clinical Pharmacology. 2021 ; 61( 3): 319-327.[citado 2024 nov. 16 ] Available from: https://doi.org/10.1002/jcph.1745
Artigo de periodico
Limited sampling modeling for estimation of phenotypic metrics for CYP enzymes and the ABCB1 transporter using a cocktail approach (2020)
Coelho, Eduardo Barbosa ; Cusinato, Diego Alberto Ciscato ; Ximenez, João Paulo Bianchi ; Lanchote, Vera Lucia ; Struchiner, Claudio José; Suarez-Kurtz, Guilherme
Source: Frontiers in Pharmacology. Unidades: FMRP, FCFRP
Subjects: CAFEÍNA, ANTI-HISTAMÍNICOS, FÁRMACOS (SISTEMA DIGESTÓRIO), FENÓTIPOS
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
COELHO, Eduardo Barbosa et al. Limited sampling modeling for estimation of phenotypic metrics for CYP enzymes and the ABCB1 transporter using a cocktail approach. Frontiers in Pharmacology, v. 11, p. 1-7, 2020Tradução . . Disponível em: https://doi.org/10.3389/fphar.2020.00022. Acesso em: 16 nov. 2024.
APA
Coelho, E. B., Cusinato, D. A. C., Ximenez, J. P. B., Lanchote, V. L., Struchiner, C. J., & Suarez-Kurtz, G. (2020). Limited sampling modeling for estimation of phenotypic metrics for CYP enzymes and the ABCB1 transporter using a cocktail approach. Frontiers in Pharmacology, 11, 1-7. doi:10.3389/fphar.2020.00022
NLM
Coelho EB, Cusinato DAC, Ximenez JPB, Lanchote VL, Struchiner CJ, Suarez-Kurtz G. Limited sampling modeling for estimation of phenotypic metrics for CYP enzymes and the ABCB1 transporter using a cocktail approach [Internet]. Frontiers in Pharmacology. 2020 ; 11 1-7.[citado 2024 nov. 16 ] Available from: https://doi.org/10.3389/fphar.2020.00022
Vancouver
Coelho EB, Cusinato DAC, Ximenez JPB, Lanchote VL, Struchiner CJ, Suarez-Kurtz G. Limited sampling modeling for estimation of phenotypic metrics for CYP enzymes and the ABCB1 transporter using a cocktail approach [Internet]. Frontiers in Pharmacology. 2020 ; 11 1-7.[citado 2024 nov. 16 ] Available from: https://doi.org/10.3389/fphar.2020.00022
Artigo de periodico-carta/editorial
Nonrelevant pharmacokinetic drug-drug interaction between furosemide and pindolol enantiomers in hypertensive parturient women [Carta] (2020)
Gonçalves, Paulo Vinícius Bernardes; Moreira, Fernanda de Lima; Benzi, Jhohann Richard de Lima ; Cavalli, Ricardo de Carvalho; Duarte, Geraldo; Lanchote, Vera Lucia
Source: The Journal of Clinical Pharmacology. Unidades: FCFRP, FMRP
Subjects: FARMACOCINÉTICA, TRABALHO DE PARTO INDUZIDO, HIPERTENSÃO NA GRAVIDEZ
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
GONÇALVES, Paulo Vinícius Bernardes et al. Nonrelevant pharmacokinetic drug-drug interaction between furosemide and pindolol enantiomers in hypertensive parturient women [Carta]. The Journal of Clinical Pharmacology. Hoboken: Faculdade de Ciências Farmacêuticas de Ribeirão Preto, Universidade de São Paulo. Disponível em: https://doi.org/10.1002/jcph.1719. Acesso em: 16 nov. 2024. , 2020
APA
Gonçalves, P. V. B., Moreira, F. de L., Benzi, J. R. de L., Cavalli, R. de C., Duarte, G., & Lanchote, V. L. (2020). Nonrelevant pharmacokinetic drug-drug interaction between furosemide and pindolol enantiomers in hypertensive parturient women [Carta]. The Journal of Clinical Pharmacology. Hoboken: Faculdade de Ciências Farmacêuticas de Ribeirão Preto, Universidade de São Paulo. doi:10.1002/jcph.1719
NLM
Gonçalves PVB, Moreira F de L, Benzi JR de L, Cavalli R de C, Duarte G, Lanchote VL. Nonrelevant pharmacokinetic drug-drug interaction between furosemide and pindolol enantiomers in hypertensive parturient women [Carta] [Internet]. The Journal of Clinical Pharmacology. 2020 ; 60( 11): 1527-1529.[citado 2024 nov. 16 ] Available from: https://doi.org/10.1002/jcph.1719
Vancouver
Gonçalves PVB, Moreira F de L, Benzi JR de L, Cavalli R de C, Duarte G, Lanchote VL. Nonrelevant pharmacokinetic drug-drug interaction between furosemide and pindolol enantiomers in hypertensive parturient women [Carta] [Internet]. The Journal of Clinical Pharmacology. 2020 ; 60( 11): 1527-1529.[citado 2024 nov. 16 ] Available from: https://doi.org/10.1002/jcph.1719
Artigo de periodico
Direct chiral LC-MS/MS analysis of fexofenadine enantiomers in plasma and urine with application in a maternal-fetal pharmacokinetic study (2020)
Pinto, Leonardo Santos Ribeiro; Vale, Gabriel Tavares do ; Moreira, Fernanda de Lima ; Pereira, Maria Paula Marques ; Coelho, Eduardo Barbosa ; Cavalli, Ricardo de Carvalho ; Lanchote, Vera Lucia
Source: Journal of Chromatography B. Unidades: FCFRP, FMRP, EERP
Subjects: ANTI-HISTAMÍNICOS, FARMACOCINÉTICA, CROMATOGRAFIA LÍQUIDA DE ALTA PRESSÃO, PLASMA, GRAVIDEZ, ESPECTROMETRIA DE MASSAS
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
PINTO, Leonardo Santos Ribeiro et al. Direct chiral LC-MS/MS analysis of fexofenadine enantiomers in plasma and urine with application in a maternal-fetal pharmacokinetic study. Journal of Chromatography B, v. 1145, 2020Tradução . . Disponível em: https://doi.org/10.1016/j.jchromb.2020.122094. Acesso em: 16 nov. 2024.
APA
Pinto, L. S. R., Vale, G. T. do, Moreira, F. de L., Pereira, M. P. M., Coelho, E. B., Cavalli, R. de C., & Lanchote, V. L. (2020). Direct chiral LC-MS/MS analysis of fexofenadine enantiomers in plasma and urine with application in a maternal-fetal pharmacokinetic study. Journal of Chromatography B, 1145. doi:10.1016/j.jchromb.2020.122094
NLM
Pinto LSR, Vale GT do, Moreira F de L, Pereira MPM, Coelho EB, Cavalli R de C, Lanchote VL. Direct chiral LC-MS/MS analysis of fexofenadine enantiomers in plasma and urine with application in a maternal-fetal pharmacokinetic study [Internet]. Journal of Chromatography B. 2020 ; 1145[citado 2024 nov. 16 ] Available from: https://doi.org/10.1016/j.jchromb.2020.122094
Vancouver
Pinto LSR, Vale GT do, Moreira F de L, Pereira MPM, Coelho EB, Cavalli R de C, Lanchote VL. Direct chiral LC-MS/MS analysis of fexofenadine enantiomers in plasma and urine with application in a maternal-fetal pharmacokinetic study [Internet]. Journal of Chromatography B. 2020 ; 1145[citado 2024 nov. 16 ] Available from: https://doi.org/10.1016/j.jchromb.2020.122094
Artigo de periodico
Total, renal and hepatic clearances of doxorubicin and formation clearance of doxorubicinol in patients with breast cancer: estimation of doxorubicin hepatic extraction ratio (2020)
Pippa, Leandro Francisco ; Oliveira, Milena Locci de ; Rocha, Adriana; Andrade, Jurandyr Moreira de ; Lanchote, Vera Lucia
Source: Journal of Pharmaceutical and Biomedical Analysis. Unidades: FCFRP, FMRP
Subjects: ANTINEOPLÁSICOS, FARMACOCINÉTICA, VARIAÇÃO (BIOLOGIA), NEOPLASIAS MAMÁRIAS, MIOCARDIOPATIA CONGESTIVA, QUIMIOTERAPIA, CROMATOGRAFIA LÍQUIDA DE ALTA PRESSÃO, ESPECTROMETRIA DE MASSAS
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
PIPPA, Leandro Francisco et al. Total, renal and hepatic clearances of doxorubicin and formation clearance of doxorubicinol in patients with breast cancer: estimation of doxorubicin hepatic extraction ratio. Journal of Pharmaceutical and Biomedical Analysis, v. 185, 2020Tradução . . Disponível em: https://doi.org/10.1016/j.jpba.2020.113231. Acesso em: 16 nov. 2024.
APA
Pippa, L. F., Oliveira, M. L. de, Rocha, A., Andrade, J. M. de, & Lanchote, V. L. (2020). Total, renal and hepatic clearances of doxorubicin and formation clearance of doxorubicinol in patients with breast cancer: estimation of doxorubicin hepatic extraction ratio. Journal of Pharmaceutical and Biomedical Analysis, 185. doi:10.1016/j.jpba.2020.113231
NLM
Pippa LF, Oliveira ML de, Rocha A, Andrade JM de, Lanchote VL. Total, renal and hepatic clearances of doxorubicin and formation clearance of doxorubicinol in patients with breast cancer: estimation of doxorubicin hepatic extraction ratio [Internet]. Journal of Pharmaceutical and Biomedical Analysis. 2020 ; 185[citado 2024 nov. 16 ] Available from: https://doi.org/10.1016/j.jpba.2020.113231
Vancouver
Pippa LF, Oliveira ML de, Rocha A, Andrade JM de, Lanchote VL. Total, renal and hepatic clearances of doxorubicin and formation clearance of doxorubicinol in patients with breast cancer: estimation of doxorubicin hepatic extraction ratio [Internet]. Journal of Pharmaceutical and Biomedical Analysis. 2020 ; 185[citado 2024 nov. 16 ] Available from: https://doi.org/10.1016/j.jpba.2020.113231
Artigo de periodico
Effect of lercanidipine on the pharmacokinetics-pharmacodynamics of carvedilol enantiomers in patients with chronic kidney disease (2020)
Schaab, Estela Hanauer; Lanchote, Vera Lucia ; Nardotto, Glauco Henrique Balthazar ; Pereira, Maria Paula Marques ; Dantas, Márcio ; Paiva, Carlos Eduardo; Coelho, Eduardo Barbosa
Source: The Journal of Clinical Pharmacology. Unidades: FCFRP, FMRP
Subjects: NEFROPATIAS, INTERAÇÃO ENTRE ALIMENTOS E MEDICAMENTOS, FARMACOCINÉTICA
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
SCHAAB, Estela Hanauer et al. Effect of lercanidipine on the pharmacokinetics-pharmacodynamics of carvedilol enantiomers in patients with chronic kidney disease. The Journal of Clinical Pharmacology, v. 60, n. 1, p. 75-85, 2020Tradução . . Disponível em: https://doi.org/10.1002/jcph.1485. Acesso em: 16 nov. 2024.
APA
Schaab, E. H., Lanchote, V. L., Nardotto, G. H. B., Pereira, M. P. M., Dantas, M., Paiva, C. E., & Coelho, E. B. (2020). Effect of lercanidipine on the pharmacokinetics-pharmacodynamics of carvedilol enantiomers in patients with chronic kidney disease. The Journal of Clinical Pharmacology, 60( 1), 75-85. doi:10.1002/jcph.1485
NLM
Schaab EH, Lanchote VL, Nardotto GHB, Pereira MPM, Dantas M, Paiva CE, Coelho EB. Effect of lercanidipine on the pharmacokinetics-pharmacodynamics of carvedilol enantiomers in patients with chronic kidney disease [Internet]. The Journal of Clinical Pharmacology. 2020 ; 60( 1): 75-85.[citado 2024 nov. 16 ] Available from: https://doi.org/10.1002/jcph.1485
Vancouver
Schaab EH, Lanchote VL, Nardotto GHB, Pereira MPM, Dantas M, Paiva CE, Coelho EB. Effect of lercanidipine on the pharmacokinetics-pharmacodynamics of carvedilol enantiomers in patients with chronic kidney disease [Internet]. The Journal of Clinical Pharmacology. 2020 ; 60( 1): 75-85.[citado 2024 nov. 16 ] Available from: https://doi.org/10.1002/jcph.1485
Artigo de periodico
Analysis of daunorubicin and its metabolite daunorubicinol in plasma and urine with application in the evaluation of total, renal and metabolic formation clearances in patients with acute myeloid leukemia (2020)
Oliveira, Milena Locci de ; Rocha, Adriana; Nardotto, Glauco Henrique Balthazar ; Pippa, Leandro Francisco ; Simões, Belinda Pinto ; Lanchote, Vera Lucia
Source: Journal of Pharmaceutical and Biomedical Analysis. Unidades: FCFRP, FMRP
Subjects: LEUCEMIA MIELOIDE AGUDA, ANTINEOPLÁSICOS, METABÓLITOS, FARMACOCINÉTICA
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
OLIVEIRA, Milena Locci de et al. Analysis of daunorubicin and its metabolite daunorubicinol in plasma and urine with application in the evaluation of total, renal and metabolic formation clearances in patients with acute myeloid leukemia. Journal of Pharmaceutical and Biomedical Analysis, v. 191, p. 1-8, 2020Tradução . . Disponível em: https://doi.org/10.1016/j.jpba.2020.113576. Acesso em: 16 nov. 2024.
APA
Oliveira, M. L. de, Rocha, A., Nardotto, G. H. B., Pippa, L. F., Simões, B. P., & Lanchote, V. L. (2020). Analysis of daunorubicin and its metabolite daunorubicinol in plasma and urine with application in the evaluation of total, renal and metabolic formation clearances in patients with acute myeloid leukemia. Journal of Pharmaceutical and Biomedical Analysis, 191, 1-8. doi:10.1016/j.jpba.2020.113576
NLM
Oliveira ML de, Rocha A, Nardotto GHB, Pippa LF, Simões BP, Lanchote VL. Analysis of daunorubicin and its metabolite daunorubicinol in plasma and urine with application in the evaluation of total, renal and metabolic formation clearances in patients with acute myeloid leukemia [Internet]. Journal of Pharmaceutical and Biomedical Analysis. 2020 ; 191 1-8.[citado 2024 nov. 16 ] Available from: https://doi.org/10.1016/j.jpba.2020.113576
Vancouver
Oliveira ML de, Rocha A, Nardotto GHB, Pippa LF, Simões BP, Lanchote VL. Analysis of daunorubicin and its metabolite daunorubicinol in plasma and urine with application in the evaluation of total, renal and metabolic formation clearances in patients with acute myeloid leukemia [Internet]. Journal of Pharmaceutical and Biomedical Analysis. 2020 ; 191 1-8.[citado 2024 nov. 16 ] Available from: https://doi.org/10.1016/j.jpba.2020.113576
Artigo de periodico
Rheumatoid arthritis downregulates the drug transporter OATP1B1: Fluvastatin as a probe (2020)
Caris, Juciene Aparecida ; Benzi, Jhohann Richard de Lima ; Souza, Flávio Falcão Lima de; Oliveira, Renê Donizeti Ribeiro de; Donadi, Eduardo Antônio ; Lanchote, Vera Lucia
Source: European Journal of Pharmaceutical Sciences. Unidades: FMRP, FCFRP
Subjects: ARTRITE REUMATOIDE, METABOLISMO, ESTUDOS DE CASOS E CONTROLES, CITOCROMO P-450, ESTATINAS, NECROSE
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
CARIS, Juciene Aparecida et al. Rheumatoid arthritis downregulates the drug transporter OATP1B1: Fluvastatin as a probe. European Journal of Pharmaceutical Sciences, v. 146, p. 1-7, 2020Tradução . . Disponível em: https://doi.org/10.1016/j.ejps.2020.105264. Acesso em: 16 nov. 2024.
APA
Caris, J. A., Benzi, J. R. de L., Souza, F. F. L. de, Oliveira, R. D. R. de, Donadi, E. A., & Lanchote, V. L. (2020). Rheumatoid arthritis downregulates the drug transporter OATP1B1: Fluvastatin as a probe. European Journal of Pharmaceutical Sciences, 146, 1-7. doi:10.1016/j.ejps.2020.105264
NLM
Caris JA, Benzi JR de L, Souza FFL de, Oliveira RDR de, Donadi EA, Lanchote VL. Rheumatoid arthritis downregulates the drug transporter OATP1B1: Fluvastatin as a probe [Internet]. European Journal of Pharmaceutical Sciences. 2020 ; 146 1-7.[citado 2024 nov. 16 ] Available from: https://doi.org/10.1016/j.ejps.2020.105264
Vancouver
Caris JA, Benzi JR de L, Souza FFL de, Oliveira RDR de, Donadi EA, Lanchote VL. Rheumatoid arthritis downregulates the drug transporter OATP1B1: Fluvastatin as a probe [Internet]. European Journal of Pharmaceutical Sciences. 2020 ; 146 1-7.[citado 2024 nov. 16 ] Available from: https://doi.org/10.1016/j.ejps.2020.105264
Artigo de periodico
A background subtraction approach for determination of endogenous cortisol and 6β-hydroxycortisol in urine by UPLC-MS/MS with application in a within-day variability study in HIV-infected pregnant women (2020)
Benzi, Jhohann Richard de Lima ; Moreira, Fernanda de Lima; Marques, Maria Paula ; Duarte, Geraldo; Suarez-Kurtz, Guilherme; Lanchote, Vera Lucia
Source: Journal of Chromatography B. Unidades: FCFRP, FMRP
Subjects: LÍQUIDOS CORPORAIS, CROMATOGRAFIA LÍQUIDA DE ALTA PRESSÃO, CITOCROMO P-450, INFECÇÕES POR HIV, CORTISOL, ESPECTROMETRIA DE MASSAS, FENÓTIPOS, GRAVIDEZ
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
BENZI, Jhohann Richard de Lima et al. A background subtraction approach for determination of endogenous cortisol and 6β-hydroxycortisol in urine by UPLC-MS/MS with application in a within-day variability study in HIV-infected pregnant women. Journal of Chromatography B, v. 1144 , 2020Tradução . . Disponível em: https://doi.org/10.1016/j.jchromb.2020.122074. Acesso em: 16 nov. 2024.
APA
Benzi, J. R. de L., Moreira, F. de L., Marques, M. P., Duarte, G., Suarez-Kurtz, G., & Lanchote, V. L. (2020). A background subtraction approach for determination of endogenous cortisol and 6β-hydroxycortisol in urine by UPLC-MS/MS with application in a within-day variability study in HIV-infected pregnant women. Journal of Chromatography B, 1144 . doi:10.1016/j.jchromb.2020.122074
NLM
Benzi JR de L, Moreira F de L, Marques MP, Duarte G, Suarez-Kurtz G, Lanchote VL. A background subtraction approach for determination of endogenous cortisol and 6β-hydroxycortisol in urine by UPLC-MS/MS with application in a within-day variability study in HIV-infected pregnant women [Internet]. Journal of Chromatography B. 2020 ; 1144 [citado 2024 nov. 16 ] Available from: https://doi.org/10.1016/j.jchromb.2020.122074
Vancouver
Benzi JR de L, Moreira F de L, Marques MP, Duarte G, Suarez-Kurtz G, Lanchote VL. A background subtraction approach for determination of endogenous cortisol and 6β-hydroxycortisol in urine by UPLC-MS/MS with application in a within-day variability study in HIV-infected pregnant women [Internet]. Journal of Chromatography B. 2020 ; 1144 [citado 2024 nov. 16 ] Available from: https://doi.org/10.1016/j.jchromb.2020.122074
Artigo de periodico
Plasma mevalonic acid exposure as a pharmacodynamic biomarker of fluvastatin/atorvastatin in healthy volunteers (2020)
Cestari, Roberta Natália ; Caris, Juciene Aparecida ; Rocha, Adriana; Nardotto, Glauco Henrique Balthazar ; Oliveira, Renê Donizeti Ribeiro de; Lanchote, Vera Lucia
Source: Journal of Pharmaceutical and Biomedical Analysis. Unidades: FCFRP, FMRP
Subjects: ESTATINAS, FARMACOCINÉTICA, FARMACOLOGIA, CROMATOGRAFIA LÍQUIDA DE ALTA PRESSÃO, COMPOSTOS ORGÂNICOS, ESPECTROMETRIA DE MASSAS
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
CESTARI, Roberta Natália et al. Plasma mevalonic acid exposure as a pharmacodynamic biomarker of fluvastatin/atorvastatin in healthy volunteers. Journal of Pharmaceutical and Biomedical Analysis, v. 182, p. 1-7, 2020Tradução . . Disponível em: https://doi.org/10.1016/j.jpba.2020.113128. Acesso em: 16 nov. 2024.
APA
Cestari, R. N., Caris, J. A., Rocha, A., Nardotto, G. H. B., Oliveira, R. D. R. de, & Lanchote, V. L. (2020). Plasma mevalonic acid exposure as a pharmacodynamic biomarker of fluvastatin/atorvastatin in healthy volunteers. Journal of Pharmaceutical and Biomedical Analysis, 182, 1-7. doi:10.1016/j.jpba.2020.113128
NLM
Cestari RN, Caris JA, Rocha A, Nardotto GHB, Oliveira RDR de, Lanchote VL. Plasma mevalonic acid exposure as a pharmacodynamic biomarker of fluvastatin/atorvastatin in healthy volunteers [Internet]. Journal of Pharmaceutical and Biomedical Analysis. 2020 ; 182 1-7.[citado 2024 nov. 16 ] Available from: https://doi.org/10.1016/j.jpba.2020.113128
Vancouver
Cestari RN, Caris JA, Rocha A, Nardotto GHB, Oliveira RDR de, Lanchote VL. Plasma mevalonic acid exposure as a pharmacodynamic biomarker of fluvastatin/atorvastatin in healthy volunteers [Internet]. Journal of Pharmaceutical and Biomedical Analysis. 2020 ; 182 1-7.[citado 2024 nov. 16 ] Available from: https://doi.org/10.1016/j.jpba.2020.113128

USP Schools

ReP

Filtros

Departament

Authors

USP affiliated authors

Date published

Subjects

Source title

Publisher

Conference titles

Countries/Territories

Funding Agencies

Indexado em

Non normalized affiliation

Countries of institutions of collaboration